$DXCM
DEXCOM INC

2014 Q4 Form 10-Q Financial Statement

#000109355714000329 Filed on November 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $84.30M $69.00M $42.90M
YoY Change 63.06% 60.84% 85.71%
Cost Of Revenue $24.90M $21.80M $15.30M
YoY Change 41.48% 42.48% 4.08%
Gross Profit $59.40M $47.20M $27.60M
YoY Change 74.19% 71.01% 228.57%
Gross Profit Margin 70.46% 68.41% 64.34%
Selling, General & Admin $36.20M $33.70M $21.60M
YoY Change 52.1% 56.02% 40.26%
% of Gross Profit 60.94% 71.4% 78.26%
Research & Development $21.60M $18.50M $11.80M
YoY Change 71.43% 56.78% 14.56%
% of Gross Profit 36.36% 39.19% 42.75%
Depreciation & Amortization $2.400M $2.200M $1.700M
YoY Change 26.32% 29.41% -19.05%
% of Gross Profit 4.04% 4.66% 6.16%
Operating Expenses $57.80M $52.20M $33.40M
YoY Change 58.79% 56.29% 29.96%
Operating Profit $1.600M -$5.000M -$5.800M
YoY Change -169.57% -13.79% -66.47%
Interest Expense -$200.0K $200.0K $200.0K
YoY Change -33.33% 0.0%
% of Operating Profit -12.5%
Other Income/Expense, Net
YoY Change
Pretax Income $1.400M -$5.200M -$6.000M
YoY Change -153.85% -13.33% -65.32%
Income Tax $100.0K $0.00 $0.00
% Of Pretax Income 7.14%
Net Earnings $1.300M -$5.200M -$6.000M
YoY Change -150.0% -13.33% -65.32%
Net Earnings / Revenue 1.54% -7.54% -13.99%
Basic Earnings Per Share
Diluted Earnings Per Share $16.95K -$68.60K -$84.03K
COMMON SHARES
Basic Shares Outstanding 76.56M shares 75.80M shares 71.40M shares
Diluted Shares Outstanding 76.10M shares 71.40M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.60M $74.90M $47.60M
YoY Change 53.11% 57.35% -10.76%
Cash & Equivalents $71.80M $63.20M $33.40M
Short-Term Investments $11.80M $11.70M $14.20M
Other Short-Term Assets $3.900M $2.800M $2.500M
YoY Change 14.71% 12.0% -7.41%
Inventory $16.00M $14.30M $10.00M
Prepaid Expenses
Receivables $42.40M $31.40M $21.60M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $145.9M $123.4M $81.70M
YoY Change 56.71% 51.04% 8.11%
LONG-TERM ASSETS
Property, Plant & Equipment $31.20M $28.00M $19.70M
YoY Change 50.72% 42.13% 5.84%
Goodwill $3.200M $3.200M $3.200M
YoY Change 0.0% 0.0% 1.2%
Intangibles $2.700M $3.100M $3.700M
YoY Change -25.0% -16.22% -14.21%
Long-Term Investments
YoY Change
Other Assets $600.0K $700.0K $800.0K
YoY Change -33.33% -12.5% 716.33%
Total Long-Term Assets $38.70M $36.00M $28.40M
YoY Change 31.63% 26.76% 4.32%
TOTAL ASSETS
Total Short-Term Assets $145.9M $123.4M $81.70M
Total Long-Term Assets $38.70M $36.00M $28.40M
Total Assets $184.6M $159.4M $110.1M
YoY Change 50.69% 44.78% 7.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.900M $7.900M $3.800M
YoY Change 135.71% 107.89% 0.0%
Accrued Expenses $27.70M $29.80M $21.20M
YoY Change 10.8% 40.57% 37.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.300M $2.300M $1.800M
YoY Change 4.55% 27.78%
Total Short-Term Liabilities $40.60M $40.60M $27.40M
YoY Change 26.48% 48.18% 34.29%
LONG-TERM LIABILITIES
Long-Term Debt $2.300M $2.900M $5.200M
YoY Change -50.0% -44.23%
Other Long-Term Liabilities $1.500M $900.0K $2.800M
YoY Change -11.76% -67.86% 78.34%
Total Long-Term Liabilities $1.500M $900.0K $2.800M
YoY Change -11.76% -67.86% 78.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.60M $40.60M $27.40M
Total Long-Term Liabilities $1.500M $900.0K $2.800M
Total Liabilities $44.40M $44.40M $35.40M
YoY Change 15.63% 25.42% 57.03%
SHAREHOLDERS EQUITY
Retained Earnings -$497.8M -$499.1M -$472.8M
YoY Change 4.71% 5.56% 8.16%
Common Stock $638.0M $614.1M $547.5M
YoY Change 14.03% 12.16% 5.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $140.2M $115.0M $74.70M
YoY Change
Total Liabilities & Shareholders Equity $184.6M $159.4M $110.1M
YoY Change 50.69% 44.78% 7.11%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income $1.300M -$5.200M -$6.000M
YoY Change -150.0% -13.33% -65.32%
Depreciation, Depletion And Amortization $2.400M $2.200M $1.700M
YoY Change 26.32% 29.41% -19.05%
Cash From Operating Activities $8.400M $11.40M $1.600M
YoY Change 90.91% 612.5% -126.67%
INVESTING ACTIVITIES
Capital Expenditures -$4.600M -$3.700M -$2.200M
YoY Change 100.0% 68.18% -24.14%
Acquisitions
YoY Change
Other Investing Activities -$100.0K -$100.0K $3.900M
YoY Change -103.57% -102.56% -38.1%
Cash From Investing Activities -$4.700M -$3.800M $1.700M
YoY Change -1040.0% -323.53% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.900M 6.100M 1.900M
YoY Change 0.0% 221.05% 46.15%
NET CHANGE
Cash From Operating Activities 8.400M 11.40M 1.600M
Cash From Investing Activities -4.700M -3.800M 1.700M
Cash From Financing Activities 4.900M 6.100M 1.900M
Net Change In Cash 8.600M 13.70M 5.200M
YoY Change -12.24% 163.46% -500.0%
FREE CASH FLOW
Cash From Operating Activities $8.400M $11.40M $1.600M
Capital Expenditures -$4.600M -$3.700M -$2.200M
Free Cash Flow $13.00M $15.10M $3.800M
YoY Change 94.03% 297.37% -222.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Interest Expense
InterestExpense
600000 USD
CY2013Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14100000 USD
CY2014Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
20900000 USD
CY2013Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4200000 USD
CY2014Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7900000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-300000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-100000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
559500000 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
614100000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35700000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18000000 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6600000 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13800000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
300000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
300000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10300000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10300000 shares
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8100000 shares
CY2013Q4 us-gaap Assets
Assets
122500000 USD
CY2014Q3 us-gaap Assets
Assets
159400000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
123400000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
93100000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
11400000 USD
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
11700000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11400000 USD
CY2014Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
11700000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
CY2012Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
2200000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63200000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43200000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8100000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33400000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20000000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25300000 USD
CY2014Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
74900000 USD
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
28700000 USD
CY2014Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
24500000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72800000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76700000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72500000 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76400000 shares
CY2014Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
100000 USD
CY2013Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
100000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27200000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23700000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5100000 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
21800000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
57400000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
40900000 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
14800000 USD
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
21800000 USD
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
15300000 USD
us-gaap Cost Of Revenue
CostOfRevenue
42300000 USD
us-gaap Cost Of Revenue
CostOfRevenue
58000000 USD
CY2012Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2016-11-01
CY2012Q4 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
13000000 USD
CY2014Q3 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
15000000 USD
CY2012 us-gaap Debt Issuance Costs
DebtIssuanceCosts
1100000 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
600000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
700000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5100000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15100000 USD
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16800000 USD
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
116600000 USD
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2200000 USD
CY2013Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1000000 USD
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-900000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-700000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
2000000 USD
CY2013Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3700000 USD
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4200000 USD
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3500000 USD
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1700000 USD
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4400000 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
200000 USD
CY2013Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2700000 USD
CY2014Q3 us-gaap Goodwill
Goodwill
3200000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
3200000 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
27600000 USD
us-gaap Gross Profit
GrossProfit
116900000 USD
CY2014Q3 us-gaap Gross Profit
GrossProfit
47200000 USD
us-gaap Gross Profit
GrossProfit
66000000 USD
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.38
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.07
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.32
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.08
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.08
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.08
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.33
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.38
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6100000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2900000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5300000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-100000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1400000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1700000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3100000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2500000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5300000 USD
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-300000 USD
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-100000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
500000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-700000 USD
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
300000 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
300000 shares
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3600000 USD
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3100000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
200000 USD
us-gaap Interest Expense
InterestExpense
600000 USD
dxcm Markto Marketon Contingent Consideration Obligation Settleablein Shares
MarktoMarketonContingentConsiderationObligationSettleableinShares
0 USD
dxcm Numberofdaysacrosslicensingcontinuationfeeisdueuponchangeofcontrol
Numberofdaysacrosslicensingcontinuationfeeisdueuponchangeofcontrol
P30D
CY2014Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6900000 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3900000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
14300000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
9000000 USD
CY2014Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6200000 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4800000 USD
CY2014Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1200000 USD
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
300000 USD
us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2014Q3 us-gaap Liabilities
Liabilities
44400000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
38400000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122500000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159400000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
40600000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32100000 USD
CY2012Q4 us-gaap Line Of Credit
LineOfCredit
15000000 USD
CY2014Q3 us-gaap Long Term Debt
LongTermDebt
5200000 USD
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
600000 USD
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2300000 USD
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2300000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (&#8220;CGM&#8221;) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;company,&#8221; or &#8220;DexCom&#8221; refer to DexCom, Inc. and its subsidiaries.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16900000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6900000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20400000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12100000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15200000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-27200000 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
900000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1700000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
12400000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-5200000 USD
us-gaap Net Income Loss
NetIncomeLoss
-23700000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-6000000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6000000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27200000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6100000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24400000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
52200000 USD
us-gaap Operating Expenses
OperatingExpenses
92600000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
33400000 USD
us-gaap Operating Expenses
OperatingExpenses
140000000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-23100000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-26600000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5800000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6200000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2600000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2900000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
700000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2300000 USD
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2200000 USD
CY2013Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4800000 USD
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7500000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
700000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
900000 USD
CY2014Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2013Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2013Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2014Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
100000 USD
dxcm Numberofdaysthecrosslicenseexpiresuponchangeofcontrolwhencrosslicensingcontinuationfeeisnotpaid
Numberofdaysthecrosslicenseexpiresuponchangeofcontrolwhencrosslicensingcontinuationfeeisnotpaid
P30D
dxcm Potential Rental Rate Adjustment Maximum
PotentialRentalRateAdjustmentMaximum
0.040
dxcm Potential Rental Rate Adjustment Minimum
PotentialRentalRateAdjustmentMinimum
0.025
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
10300000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5600000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11600000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2013Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2800000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3400000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6900000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18500000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38400000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
9800000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2500000 USD
CY2013Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1100000 USD
CY2014Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1300000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
3500000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20700000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28000000 USD
CY2014Q3 us-gaap Recorded Unconditional Purchase Obligation Due Within One Year
RecordedUnconditionalPurchaseObligationDueWithinOneYear
26900000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1600000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18500000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11800000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47800000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32200000 USD
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000 USD
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000 USD
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1000000 USD
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1000000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-499100000 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
42500000 USD
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
67900000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
172800000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-475400000 USD
CY2014Q3 us-gaap Revenues
Revenues
69000000 USD
CY2013Q3 us-gaap Revenues
Revenues
42900000 USD
us-gaap Revenues
Revenues
174900000 USD
us-gaap Revenues
Revenues
108300000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
105800000 USD
CY2013Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2200000 USD
CY2014Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
2300000 USD
CY2013Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
4600000 USD
CY2014Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
2900000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60400000 USD
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33700000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21600000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
92200000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
18000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
35700000 USD
CY2013Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
900000 USD
CY2013Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1300000 USD
CY2013Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
300000 USD
CY2014Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1200000 USD
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
300000 USD
CY2014Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
900000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
84100000 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
115000000 USD
CY2014Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
400000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt, accounting for the SweetSpot acquisition including contingent consideration, and share-based compensation expense. </font></div></div>
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71400000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75000000 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70700000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71400000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70700000 shares
CY2013Q4 dxcm Accounts Receivable Net Of Allowance And Sales Returns Current
AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent
26100000 USD
CY2014Q3 dxcm Accounts Receivable Net Of Allowance And Sales Returns Current
AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent
31400000 USD
CY2014Q3 dxcm Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
1500000 USD
CY2013Q4 dxcm Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
1200000 USD
CY2014Q3 dxcm Acquisition Related Contingent Consideration Short Term
AcquisitionRelatedContingentConsiderationShortTerm
3500000 USD
CY2013Q4 dxcm Acquisition Related Contingent Consideration Short Term
AcquisitionRelatedContingentConsiderationShortTerm
3600000 USD
CY2012 dxcm Business Acquisition Contingent Consideration Settlement
BusinessAcquisitionContingentConsiderationSettlement
1100000 USD
CY2012 dxcm Business Acquisition Contingent Consideration Settlement Shares Issued
BusinessAcquisitionContingentConsiderationSettlementSharesIssued
89296 shares
CY2014Q3 dxcm Business Acquisition Equity Interests Issued Or Issuable Additional Number Of Shares Issuable
BusinessAcquisitionEquityInterestsIssuedOrIssuableAdditionalNumberOfSharesIssuable
89300 shares
CY2012Q1 dxcm Business Combination Contingent Consideration Liability Shares
BusinessCombinationContingentConsiderationLiabilityShares
357176 shares
CY2013Q4 dxcm Clinical Trials
ClinicalTrials
300000 USD
CY2014Q3 dxcm Clinical Trials
ClinicalTrials
500000 USD
CY2013Q4 dxcm Contingent Consideration Fair Value Disclosure
ContingentConsiderationFairValueDisclosure
4200000 USD
CY2014Q3 dxcm Contingent Consideration Fair Value Disclosure
ContingentConsiderationFairValueDisclosure
3500000 USD
CY2014Q3 dxcm Crosslicensingcontinuationfeeuponchangeofcontrol
Crosslicensingcontinuationfeeuponchangeofcontrol
25000000 USD
CY2012Q4 dxcm Debt Instrument Basis Spread On Treasury Variable Rate
DebtInstrumentBasisSpreadOnTreasuryVariableRate
0.0694
CY2014Q3 dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
0 USD
dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
600000 USD
CY2013Q3 dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
500000 USD
dxcm Development And Other Cost Of Sales
DevelopmentAndOtherCostOfSales
1400000 USD
dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
2100000 USD
dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
2500000 USD
CY2014Q3 dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
1100000 USD
CY2013Q3 dxcm Development Grant And Other Revenue
DevelopmentGrantAndOtherRevenue
400000 USD
dxcm Fair Value Of Contingent Consideration
FairValueOfContingentConsideration
2000000 USD
dxcm Fair Value Of Contingent Consideration
FairValueOfContingentConsideration
-700000 USD
dxcm Markto Marketon Contingent Consideration Obligation Settleablein Shares
MarktoMarketonContingentConsiderationObligationSettleableinShares
-700000 USD
CY2013Q3 dxcm Markto Marketon Contingent Consideration Obligation Settleablein Shares
MarktoMarketonContingentConsiderationObligationSettleableinShares
0 USD
CY2014Q3 dxcm Markto Marketon Contingent Consideration Obligation Settleablein Shares
MarktoMarketonContingentConsiderationObligationSettleableinShares
-900000 USD
CY2012Q4 dxcm Prime Rate Plus
PrimeRatePlus
0.005
dxcm Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term
RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm
P1Y
CY2013 dxcm Researchand Development Arrangement Grants Received During Period
ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod
500000 USD
dxcm Researchand Development Arrangement Grants Received During Period
ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod
1500000 USD
CY2013Q3 dxcm Researchand Development Arrangement Valueof Grant
ResearchandDevelopmentArrangementValueofGrant
4000000 USD
dxcm Sales Return Coverage Period
SalesReturnCoveragePeriod
P30D
dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
3800000 USD
dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
3500000 USD
CY2013Q3 dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
2100000 USD
CY2014Q3 dxcm Standard Product Warranty Accrual Charges To Costs And Expenses
StandardProductWarrantyAccrualChargesToCostsAndExpenses
1600000 USD
CY2012Q4 dxcm Term Loan Advances Aggregate Amount
TermLoanAdvancesAggregateAmount
7000000 USD
CY2012Q4 dxcm Term Loan Debt
TermLoanDebt
20000000 USD
dxcm Term Of Lease
TermOfLease
P3Y
CY2014Q3 dxcm Working Capital
WorkingCapital
82800000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001093557
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76561868 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
DEXCOM INC
dei Trading Symbol
TradingSymbol
DXCM

Files In Submission

Name View Source Status
0001093557-14-000329-index-headers.html Edgar Link pending
0001093557-14-000329-index.html Edgar Link pending
0001093557-14-000329.txt Edgar Link pending
0001093557-14-000329-xbrl.zip Edgar Link pending
dxcm-09302014x10q.htm Edgar Link pending
dxcm-20140930.xml Edgar Link completed
dxcm-20140930.xsd Edgar Link pending
dxcm-20140930_cal.xml Edgar Link unprocessable
dxcm-20140930_def.xml Edgar Link unprocessable
dxcm-20140930_lab.xml Edgar Link unprocessable
dxcm-20140930_pre.xml Edgar Link unprocessable
dxcm09302014ex3101.htm Edgar Link pending
dxcm09302014ex3102.htm Edgar Link pending
dxcm09302014ex3201.htm Edgar Link pending
dxcm09302014ex3202.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending